ONCOLOGY COMPANION DIAGNOSTICS XCHANGE
WEST COAST
San Francisco
February 9, 2023

Welcome to hubXchange’s West Coast Oncology Companion Diagnostics Xchange 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing oncology companion diagnostics.

Discussion topics will cover Clinical Biomarkers, Clinical Development, Liquid Biopsies and Next Generation CDx.

Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.

Venue Details: DoubleTree by Hilton San Francisco Airport, 835 Airport Blvd, Burlingame CA 94010-9949

Clinical Biomarkers

Time
Titles and Bullets
Facilitator
8:00 – 8:30am
Registration 
8:30 – 9:00am

Opening Address & Keynote Presentation

9:05 – 10:05am

Validating biomarker tests to expedite approval and guide use of NDE’s [Topic TBC]

Senior Scientist, Harpoon Therapeutics

Carmela Dantas Barbosa is a knowledgeable cancer biologist with more than 20 years of experience including 5 years in pharmaceutical and biotech industry. Experienced in discovery through pre-clinical and clinical development in oncology with focus on translational medicine. Carmela is responsible for leading CDx development strategies for Tritac molecules (T-Cell engagers) spanning different cancer indications at Harpoon Therapeutics. Previously, she worked at Tizona Therapeutics and Celgene. Carmela has large experience in biomarker and bioanalytical assay development and validation, spanning multiple technology platforms.  Experienced in working with CROs in support of non-clinical and clinical programs. Carmela’s interest in translational medicine have been shaped by her experience working in 3 international hospitals. As a postdoc at Gustave Roussy Institute, the largest hospital and cancer research center in Europe and Leon Berard Center both in France and as scientist, developing molecular based diagnostic assays, at Sarah Hospital in Brazil.

Foto Carmela
10:10 – 10:40am
1-2-1 Meetings/Networking Break
10:40 – 11:10am
1-2-1 Meetings/Networking Break
11:10 – 11:20am
Morning Refreshment Break
11:20am – 12:20pm

Sponsor-led Roundtable

12:20 – 1:20pm
Networking Lunch
1:20 – 1:50pm

Spotlight Presentation

1:55 – 2:25pm
1-2-1 Meetings / Networking Break
2:25 – 2:55pm
1-2-1 Meetings / Networking Break

3:00 – 3:30pm

Poster Session

3:30 – 3:45pm
Afternoon Refreshment Break

3:45 – 4:45pm

Biomarkers for cancer immunotherapy: clinical implications

Chief Medical Officer, ASC
Therapeutics

Former CMO for Symvivo, Myriad Genetics and CellMax Life, Vice President for Becton Dickinson and Global Medical Head for Abbott/AbbVie (Humira).  Executive veteran with extensive global leadership experience in translational science, clinical development and global regulatory and medical affairs.

Author and co-author of over 100 peer-reviewed publications, including Nature and Lancet, books and medical articles and member of several scientific and medical societies. Forbes Council Board Member. Holding a tenured Professorship of Immunology at the University of Leon, Spain. Received PhD from the University of Wuerzburg, Germany and MD from the University of Salamanca, Spain.

Photo_Oscar Segurado_N1c
4:50  5:50pm

Use of predictive/prognostic markers for co-development of diagnostic tools

Director, Clinical Biomarkers
Compugen

Yu Liang is currently Director of Clinical Biomarkers at Compugen heading implementation of biomarkers in clinical trials to develop drugs targeting immune checkpoints. He brings in 20 years of expertise and leadership in precision medicine, including assay development in research and IVD, and application of genomic and genetic profiling for patient stratification. Before Compugen, he was Director of Translational Sciences in Oncology at Ipsen, leading translation of pre-clinical biomarkers into early phase clinical trials. Prior to Ipsen, he led development of clinical biomarker for drugs targeting amino acid metabolism at Calithera and managed the clinical biomarker portfolios of Ibrutinib for non-Hodgkin’s lymphomas at Pharmacyclics.

Portrait picture of Yu Liang
5:50 – 6:50pm
Canape / Drinks Reception

Lead Partner

Partners

Oncology Companion Diagnostics Xchange | West Coast 2023
Register